Glycomet-GP 4 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 4 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral insulin sensitivity, and enhancing glucose uptake in muscle tissues. This dual mechanism addresses both insulin deficiency and insulin resistance, offering effective glycemic control. Glycomet-GP 4 Forte Tablet PR is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy for optimal blood glucose management. It is essential to administer this medication with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea and diarrhea. Regular monitoring of blood glucose levels, renal function, and hepatic parameters is recommended during therapy. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis. Glycomet-GP 4 Forte Tablet PR should be used under medical supervision, with dose adjustments based on therapeutic response and tolerability to achieve and maintain target glycemic control.